|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01515 CR MEDICAL
Nominal 
3.910 -0.030 (-0.761%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 10,107,500 | 27.922% | 7,901,287 | 4,447,477 | 2,750,650 | 2,115,320 |
| Cost of Sales | (8,201,663) | 24.353% | (6,595,452) | (3,513,922) | (2,114,143) | (1,353,029) |
| Gross Profit | 1,905,837 | 45.948% | 1,305,835 | 933,555 | 636,507 | 762,291 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | (208,926) | 40865.882% | (510) | -- | -- | -- | |
| Change in FV & Impairment on Others | (272,228) | 99.976% | (136,130) | (355,289) | (23,525) | (1,577) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 90,780 | 3.079% | 88,068 | 83,554 | 34,968 | 4,646 | |
| Profit / (Loss) before Taxation | 492,921 | 16.546% | 422,941 | 270,475 | 418,185 | 541,299 | |
| Taxation | (165,031) | 74.341% | (94,660) | 155,389 | (97,864) | (140,665) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (70,210) | 12.469% | (62,426) | (7,949) | (10,190) | (9,769) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 257,680 | -3.075% | 265,855 | 417,915 | 310,131 | 390,865 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 46,502 | -- | (22,202) | (59,612) | (62,539) | (48,042) |
| Depreciation & Amortisation | 610,863 | 25.587% | 486,406 | 182,879 | 113,382 | 63,644 |
| Directors' Emoluments | 10,515 | -0.970% | 10,618 | 13,079 | 18,418 | 23,782 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 20.000 | -4.762% | 21.000 | 33.000 | 25.000 | 31.000 |
| DPS (cts) | 6.000 | -- | 3.344 | 10.238 | 7.400 | 9.000 |
| Dividend Payout Ratio (%) | 30.000% | -- | 15.923% | 31.024% | 29.600% | 29.032% |
| Cash flow per share ($) | 0.945 | -- | 0.684 | 0.566 | 0.513 | 0.292 |
| NBV per share ($) | 4.482 | -- | 7.331 | 4.975 | 4.709 | 4.553 |
| Remarks: | Real time quote last updated: 19/11/2024 12:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 433,949 |
| %Change | 9.121% |
| EPS / (LPS) | RMB 0.340 |
| NBV Per Share (¥) | RMB 4.758 |